HPV Associated Disorders Global Market Report 2024

The disorders associated with the human papillomavirus pertain to a virus capable of triggering abnormal tissue growth, such as warts and various cell irregularities. Transmission of these disorders primarily occurs through sexual intercourse or other forms of skin-to-skin contact. Vaccination, medications, and other diagnostic measures can aid in safeguarding against HPV types that lead to HPV-related cancer.

The primary manifestations of HPV-associated disorders include cervical intraepithelial neoplasia (CIN), cervical cancer, anal intraepithelial neoplasia (AIN), anal cancer, genital warts, and other indications. The cervical intraepithelial indication of HPV-associated disorder is employed for the prevention and treatment of cervical intraepithelial neoplasia. Cervical intraepithelial neoplasia (CIN) denotes abnormal alterations in the cells lining the cervix. The management of HPV-associated disorders involves preventive and therapeutic measures, which are accessible through hospital pharmacies, retail pharmacies, and online pharmacies.

The HPV associated disorders market research report is one of a series of new reports that provides HPV associated disorders market statistics, including HPV associated disorders industry global market size, regional shares, competitors with a HPV associated disorders market share, detailed HPV associated disorders market segments, market trends and opportunities, and any further data you may need to thrive in the HPV associated disorders industry. This HPV associated disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hpv associated disorders market size has grown strongly in recent years. It will grow from $19.42 billion in 2023 to $20.97 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The expansion during the historical period can be ascribed to the increasing prevalence of HPV-associated disorders, a heightened awareness of HPV and its related conditions, advancements in diagnostic technologies, government initiatives promoting HPV vaccination programs, and a growing demand for early screening and vaccination.

The hpv associated disorders market size is expected to see strong growth in the next few years. It will grow to $27.82 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The anticipated growth in the forecast period can be linked to the approval of new HPV vaccines, heightened initiatives by both government and private organizations for early screening and vaccination, an upsurge in the incidence of cervical cancer, an increasing demand for non-invasive diagnostic tests, and the integration of HPV testing into routine healthcare. Prominent trends expected in the forecast period encompass the development of next-generation HPV vaccines, the adoption of point-of-care HPV testing, a shift towards molecular techniques in HPV detection, personalized approaches in HPV management, and the integration of HPV testing within women's health services.

The HPV-associated disorders market is expected to witness growth due to an increased prevalence of HPV-related cases. These disorders encompass a range from benign verrucae vulgates and condylomas acuminata to malignancies such as cervical, vulva, anus, and penis cancers, as well as anogenital warts, recurrent respiratory papillomatosis, and anogenital and oropharyngeal cancers. The global burden is significant, particularly among women. For instance, a report from cancer. net in January 2022 estimated that 14,100 women in the United States would be diagnosed with invasive cervical cancer, and globally, 604,127 women were diagnosed with cervical cancer in 2020. Additionally, in 2023, an estimated 4,310 deaths from cervical cancer occurred in the United States, emphasizing the need for advancements in the HPV-associated disorders market.

A driving factor in the HPV-associated disorders market is the decline in contraceptive use. Contraceptives play a crucial role in preventing unplanned pregnancies, and a reduction in their market share can lead to an increase in the number of individuals at risk of HPV infection, a known risk factor for disorders like cervical cancer. A report in December 2022 revealed an 8% reduction in the overall value of the public-sector contraceptive market across 83 Low and Middle-Income Countries (LMICs). This decline, from $285 million in 2020 to $263 million in 2021, underscores the impact on the HPV-associated disorders market.

A notable trend in the HPV-associated disorders market is the growing popularity of targeted therapies. Key players are developing and adopting therapies specifically designed to treat HPV-associated disorders, including cervical and oropharyngeal cancers. These targeted therapies focus on proteins like vascular endothelial growth factor and tissue-factor (TF) in cancer cells. An example is the FDA approval of Genmab A/S and Seagen Inc. 's drug Tivdak (tisotumab vedotin-tftv) in September 2021 for recurrent or metastatic cervical cancer post-chemotherapy, indicating a shift toward more effective treatment options.

Leading companies in the HPV-associated disorders market are introducing gender-neutral HPV vaccines to combat HPV-related diseases. These vaccines are recommended and administered to individuals of all genders to protect against HPV, which can lead to various cancers. In September 2021, MSD Pharmaceuticals launched GARDASIL 9, the first gender-neutral HPV vaccine in India, aiming to reduce HPV-related diseases and cancers in both girls and women (aged 9-26 years) and boys (aged 9-15 years). This vaccine, a 9-valent Human Papillomavirus (HPV) vaccine, is designed to prevent diseases and cancers caused by specific HPV types, with dosing schedules determined by healthcare professionals.

In May 2022, GlaxoSmithKline plc, a UK-based biopharmaceutical company, acquired Affinivax, Inc. for $2.1 billion. This strategic acquisition enhances GSK plc's vaccine R&D pipeline by providing access to Affinivax's innovative vaccine technology platform, MAPS (Multiple Antigen Presenting System). Affinivax, Inc., a US-based clinical-stage biopharmaceutical company, specializes in developing next-generation vaccine technology platforms.

Major companies operating in the in the hpv associated disorders market report are AstraZeneca plc, F. Hoffmann-La Roche Ltd, Biocon Ltd, GlaxoSmithKline plc, Merck & Co Inc., Pfizer Inc., Eli Lilly and Company, Sanofi S. A., Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Celgene Corporation, Gilead Sciences Inc., Ipsen S. A., Mylan N. V., Teva Pharmaceutical Industries Ltd., Bayer AG, Eisai Co. Ltd., Genentech Inc., Medtronic plc, Novo Nordisk A/S, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, CSL Limited, Lupin Limited

North America was the largest region in the HPV associated disorders market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hpv associated disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hpv associated disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The human papillomavirus-associated disorders market includes revenues earned by entities by plantar warts and flat warts. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.